<DOC>
	<DOCNO>NCT00432081</DOCNO>
	<brief_summary>The purpose study determine whether indomethacin able retard disease progression patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Effect Indomethacin Progression Alzheimer 's Disease</brief_title>
	<detailed_description>Previous research indicate inflammation play role pathogenesis Alzheimer ’ disease ( AD ) , nonsteroidal anti-inflammatory drug ( NSAIDs ) may retard progression disease . Comparison ( ) : Cognitive decline patient mild moderate AD receiving NSAID indomethacin , compare cognitive decline patient mild moderate AD receiving placebo , one-year period .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>The patient satisfy DSMIV criterion dementia Alzheimer ’ type . The patient satisfy NINCDS/ADRDA criterion clinical diagnosis probable Alzheimer ’ disease ( Appendix I ) . The severity dementia patient quantify MiniMental State Examination ( MMSE ) score 10 26 ( inclusive ) . The patient living home home elderly . The patient responsible caregiver able provide information patient ’ functional status . Written inform consent obtain patient legally accept representative . The patient satisfies NINDSAIREN criterion probable vascular dementia . A know exaggerated pharmacological sensitivity allergy NSAID ’ . History peptic ulceration , gastric surgery gastrointestinal bleeding . Current diagnosis active peptic ulceration . Current diagnosis severe unstable cardiovascular disease . Current diagnosis renal failure . Advanced , severe unstable disease type , Alzheimer ’ disease , may interfere primary secondary variable evaluation , include medical condition expect progress , recur , change extent may bias assessment clinical mental status patient significant degree put patient special risk . Intake follow concomitant medication : salicylate , coumarin derivative , ACEinhibitors , loop diuretic . Intake follow concomitant medication two month immediately prior study : NSAID ’ , systemic corticosteroid . Intake follow concomitant medication possible effect cognition : estrogen , deprenyl , vitamin E , neuroleptic , anticholinergic . Patients use stable dos cholinesterase inhibitor eligible , provision dose change study . Cholinesterase inhibitor could initiate study . Excessive use alcohol ( 5 unit per day ) The patient , either alone aid caregiver , able reliably take medication .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Anti-Inflammatory Agents , Non-Steroidal</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>